Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview
Despite initial response to androgen inhibition, metastatic prostate cancer is invariably an incurable disease. New agents with different mechanisms of action are needed that are capable of producing clinical benefit and prolonging survival. New breakthroughs specific to prostate cancer are being...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2024-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/467298 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Despite initial response to androgen inhibition, metastatic prostate cancer is invariably
an incurable disease. New agents with different mechanisms of action are needed that are capable of
producing clinical benefit and prolonging survival. New breakthroughs specific to prostate cancer are being
made by combining novel diagnostic molecular imaging modalities with cytotoxic radionuclide payloads
to cancer cells and the surrounding tumor microenvironment. This concept yielded unprecedented
clinical responses in a very challenging population of patients. Targeted radionuclide therapy, mainly
targeting prostate-specific antigen (PSMA), is now considered the new standard of care for patients
with advanced disease who have progressed to the use of new androgen suppressors and chemotherapy.
Targeted radionuclide therapy, mainly focused on prostate-specific antigen, is now considered the new
treatment standard for patients with more aggressive disease who have been treated with new androgen
suppressors and chemotherapy. The application of the theranostic paradigm has enabled personalized
management of prostate cancer patients, with significant potential for future development in the form
of a combination therapy with other agents. This freeform review article summarizes the key clinical
research in the field of radionuclide targeted therapy for prostate cancer and provides an overview of
current practice in this rapidly evolving entity. |
|---|---|
| ISSN: | 0353-9466 1333-9451 |